Navigation Links
Trius' Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
Date:9/12/2009

SAN DIEGO, Sept. 12 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA. Additional data from a previously announced Phase 2 study of torezolid (TR-701) reiterate the high efficacy of torezolid at the low 200 mg dose against methicillin-sensitive and methicillin-resistant bacteria in patients with severe complicated skin and skin structure infections (cSSSI). In vitro studies presented at ICAAC highlight the potency of torezolid against linezolid-resistant MRSA and cfr-mediated resistant bacteria.

"The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against bacterial strains proven to be resistant to linezolid," said Philippe Prokocimer, M.D., chief medical officer at Trius." There is an urgent need for more potent antibiotics like torezolid with different mechanisms of action that can circumvent drug resistance pathways."

ICAAC data presentations are as follows:

Saturday, September 12

(Poster Session 024, 11:30 am - 1:30 pm)

  • L1-335/355: Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI)

(Poster Session 004, 11:30 am - 1:30 pm)

  • B-050/52: Comparative Efficacy of TR-701, Vancomycin (Vanco), and Daptomycin (Dapto) in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Endocarditis

Sunday, September 13

(Poster Session 082a, 11:15 am - 1:15 pm)

  • E-808/275: Activity of Torezolid against linezolid-resistant MRSA strains with cfr gene mediated resistance
  • E-807/274: Comparative Activity of TR-700 Against Staphylococci Blood Isolates Collected in Spain
  • E-809/276: In Vitro Activity of Torezolid (TR-700) versus Linezolid against Chlamydia species

Monday, September 14

(Poster Session 155, 11:15 am - 1:15 pm)

  • C1-1346/84: Unexpectedly low cost of fitness associated with acquisition of the cfr resistance gene
  • C1-1364b/104: Genetic Environment and Instability of cfr in MRSA CM05
  • C1-1364a/103: In vitro Activity of TR-700 (Torezolid) and Linezolid against Gram-positive Clinical Isolates from a Phase 2 Complicated Skin Clinical Trial
  • C1-1349/87: Mutations in Ribosomal Protein L3 are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin

Tuesday, September 15

(Poster Session 226, 9:00 am - 11:00 am)

  • A1-1939/12: Compararative Pharmacodynamics of a Novel Oxazolidinone, TR-701, Against S. aureus in a Neutropenic Murine Pneumonia Infection Model
  • A1-1935/8: Defining the Impact of Granulocytes (G) on the Kill of Methicillin-Resistant Staphylococcus aureus (MRSA) by the New Oxazolidanone Prodrug TR-701
  • A1-1947/20: Evaluation of Tissue Distribution of TR-700 in Healthy Volunteers, Using Microdialysis
  • A1-1934/7: Torezolid (TR-700), a novel methyltetrazolyl-oxazolidinone, accumulates markedly within human THP-1 macrophages and shows activity towards intraphagocytic Legionella pneumophila: comparison with linezolid

Copies of these posters will be available on the Trius Web site following the ICAAC meeting.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently marketed antibacterial drug of the oxazolidinone class. Trius' pipeline includes two preclinical programs with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
2. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
3. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Trius Doses First Patient in Antibacterial Phase 2 Trial
6. PacificGMP Completes GMP Product Fill for Trius Therapeutics
7. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
8. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
9. NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
10. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
11. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was announced in February and ... WUGC is being held in London, England this year from June 18-25. At the last ... gold in the women’s masters division, and a silver in the women’s division, so Mazur ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... will be held at the Bellagio Hotel in Las Vegas, NV from October ... (NASW) will be co-hosting the event. , This year’s conference will offer ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t ... number five on the list of “ 5 US Cities with the Highest Plastic Rates ... Angeles, and Miami. The results were calculated using a survey by RealSelf ...
(Date:5/2/2016)... Ocean City, MD (PRWEB) , ... May 02, 2016 , ... ... high quality SUP boards at affordable prices announced today the outcome of their partnership ... what has been termed the “Roots Yoga Board.” , SUP yoga has seen a ...
(Date:5/2/2016)... ... May 02, 2016 , ... In response to recent growth and ... Low Vision and Blindness (NELV&B) , announces the opening of a new low vision ... with vision impairments to get assessments, hands-on experience and training with low vision and ...
Breaking Medicine News(10 mins):